Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding. 1998

J R Jasper, and J D Lesnick, and L K Chang, and S S Yamanishi, and T K Chang, and S A Hsu, and D A Daunt, and D W Bonhaus, and R M Eglen
Center for Biological Research, Neurobiology Unit, Roche Bioscience, Palo Alto, CA 94304, USA. jeffrey.jasper@roche.com

Alpha-2 adrenergic receptors (alpha2 AR) mediate incorporation of guanosine 5'-O-(gamma-thio)triphosphate ([35S]GTPgammaS) into isolated membranes via receptor-catalyzed exchange of [35S]GTPgammaS for GDP. In the current study, we used [35S]GTPgammaS incorporation to characterize the intrinsic activity and potency of agonists and antagonists at the cloned mouse alpha2a/d and human alpha2a, alpha2b, and alpha2c ARs. Full agonists increased [35S]GTPgammaS binding to membranes by 2- to 3-fold. Antagonists did not increase [35S]GTPgammaS binding but competitively inhibited agonist-stimulated [35S]GTPgammaS binding. Compounds with intrinsic activities less than that of the full agonists norepinephrine (NE) or epinephrine (EPI) were capable of antagonizing agonist-stimulated [35S]GTPgammaS binding. The agonistic properties of a number of alpha2 AR ligands were characterized at each alpha2 AR subtype. The rank order of agonist potency for selected compounds at the human receptors (with intrinsic activity compared with NE, defined as 1.0) was: alpha2a: Dexmedetomidine (0.73) > guanabenz (0.38) > UK-14304 (1.02) > clonidine (0.32) > ST-91 (0.63) > NE (1.00). alpha2b: Dexmedetomidine (1.10) > clonidine (0.18) > guanabenz (0.71) > NE (1.00) > ST-91 (0.44) > UK-14304 (0.59). alpha2c: Dexmedetomidine (1.03) > NE (1.00) > UK-14304 (0.75) > ST-91 (0.32) > or = clonidine (0.23) >> guanabenz (0). This report provides a functional characterization of adrenergic receptor ligands at human and mouse alpha2a/d AR. It also illustrates the utility of [35S]GTPgammaS incorporation as a functional marker of receptor activation.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011807 Quinolizines
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D005822 Genetic Vectors DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition. Cloning Vectors,Shuttle Vectors,Vectors, Genetic,Cloning Vector,Genetic Vector,Shuttle Vector,Vector, Cloning,Vector, Genetic,Vector, Shuttle,Vectors, Cloning,Vectors, Shuttle
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000242 Cyclic AMP An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH. Adenosine Cyclic 3',5'-Monophosphate,Adenosine Cyclic 3,5 Monophosphate,Adenosine Cyclic Monophosphate,Adenosine Cyclic-3',5'-Monophosphate,Cyclic AMP, (R)-Isomer,Cyclic AMP, Disodium Salt,Cyclic AMP, Monoammonium Salt,Cyclic AMP, Monopotassium Salt,Cyclic AMP, Monosodium Salt,Cyclic AMP, Sodium Salt,3',5'-Monophosphate, Adenosine Cyclic,AMP, Cyclic,Adenosine Cyclic 3',5' Monophosphate,Cyclic 3',5'-Monophosphate, Adenosine,Cyclic Monophosphate, Adenosine,Cyclic-3',5'-Monophosphate, Adenosine,Monophosphate, Adenosine Cyclic

Related Publications

J R Jasper, and J D Lesnick, and L K Chang, and S S Yamanishi, and T K Chang, and S A Hsu, and D A Daunt, and D W Bonhaus, and R M Eglen
January 1999, Life sciences,
J R Jasper, and J D Lesnick, and L K Chang, and S S Yamanishi, and T K Chang, and S A Hsu, and D A Daunt, and D W Bonhaus, and R M Eglen
August 1998, European journal of pharmacology,
J R Jasper, and J D Lesnick, and L K Chang, and S S Yamanishi, and T K Chang, and S A Hsu, and D A Daunt, and D W Bonhaus, and R M Eglen
August 1998, European journal of pharmacology,
J R Jasper, and J D Lesnick, and L K Chang, and S S Yamanishi, and T K Chang, and S A Hsu, and D A Daunt, and D W Bonhaus, and R M Eglen
May 2000, Naunyn-Schmiedeberg's archives of pharmacology,
J R Jasper, and J D Lesnick, and L K Chang, and S S Yamanishi, and T K Chang, and S A Hsu, and D A Daunt, and D W Bonhaus, and R M Eglen
April 1998, Journal of neurochemistry,
J R Jasper, and J D Lesnick, and L K Chang, and S S Yamanishi, and T K Chang, and S A Hsu, and D A Daunt, and D W Bonhaus, and R M Eglen
January 2008, Neuroendocrinology,
J R Jasper, and J D Lesnick, and L K Chang, and S S Yamanishi, and T K Chang, and S A Hsu, and D A Daunt, and D W Bonhaus, and R M Eglen
July 1999, British journal of pharmacology,
J R Jasper, and J D Lesnick, and L K Chang, and S S Yamanishi, and T K Chang, and S A Hsu, and D A Daunt, and D W Bonhaus, and R M Eglen
June 2008, Pharmacological research,
J R Jasper, and J D Lesnick, and L K Chang, and S S Yamanishi, and T K Chang, and S A Hsu, and D A Daunt, and D W Bonhaus, and R M Eglen
January 2000, Neuropharmacology,
J R Jasper, and J D Lesnick, and L K Chang, and S S Yamanishi, and T K Chang, and S A Hsu, and D A Daunt, and D W Bonhaus, and R M Eglen
May 2000, Molecular psychiatry,
Copied contents to your clipboard!